Search

Displaying results 71 - 80 of 441 in total
  1. Drug

    Triazolam

    go.drugbank.com/drugs/DB00897
    ApprovedInvestigational

    Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.

    Products: Alti-triazolam Tab 0.25mg, Alti-triazolam Tab 0.125mg
  2. Drug

    Susoctocog alfa

    go.drugbank.com/drugs/DB11606
    ApprovedInvestigational

    Susoctocog alfa serves to temporarily restore the inhibited endogenous Factor VIII for effective hemostasis. … Susoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for intravenous injection.

    Categories: susoctocog alfaSynonyms: Susoctocog alfa
  3. Drug

    Prazosin

    go.drugbank.com/drugs/DB00457
    ApprovedInvestigational

    Prazosin is a drug used to treat hypertension. Prazosin is marketed by Pfizer and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists. Recently, many studies have evaluated the benefit...

    Products: Alti-prazosin-tab 1mg, Alti-prazosin-tab 2mg
  4. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Asfotase Alfa is marketed under the brand name Strensiq® by Alexion Pharmaceuticals, Inc. The annual average price of Asfotase Alfa treatment is $285,000. … Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP).

    Categories: asfotase alfaSynonyms: Asfotase alfa
  5. Drug

    Ropeginterferon alfa-2b

    go.drugbank.com/drugs/DB15119
    ApprovedInvestigational

    [A242015, L39170] Ropeginterferon alfa-2b has shown efficacy in PV in _in vitro_ and _in vivo_ models and clinical trials. … [A242000, A242005] [Interferon alfa-2b] has been used for decades to treat PV but requires frequent dosing and is not tolerated by all patients.

    Categories: Alfa Interferons, ropeginterferon alfa-2bSynonyms: PEG-P-IFN-alfa-2b, Ropeginterferon alfa-2b
  6. Drug

    Mexiletine

    go.drugbank.com/drugs/DB00379
    ApprovedInvestigational

    Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.

    Products: Alti-mexiletine
  7. Drug

    Dexbrompheniramine

    go.drugbank.com/drugs/DB00405
    Approved

    Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.

    Mixtures: Ala-hist PEProducts: Ala-hist Ir
  8. Drug

    Damoctocog alfa pegol

    go.drugbank.com/drugs/DB14700
    ApprovedInvestigational

    [A38907] Also known as, BAY94-9027, Damoctocog alfa pegol is a longer-acting Factor VIII therapy formulated with polyethylene glycol (PEG) to reduce the number of infusions necessary to prevent bleeds

    Synonyms: Damoctocog alfa pegol, Damoctocog alfa-pegol
  9. Drug

    Peginterferon alfa-2b

    go.drugbank.com/drugs/DB00022
    ApprovedInvestigational

    Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. … The use of Peginterferon alfa-2b has largely declined since newer interferon-free antiviral therapies have been developed.

    Categories: Alfa Interferons, peginterferon alfa-2bSynonyms: Peg interferon alfa-2b, Peginterferon alfa-2b
  10. Drug

    Dibotermin alfa

    go.drugbank.com/drugs/DB11639
    ApprovedInvestigational

    Dibotermin alfa is a recombinant human bone morphogenetic protein-2 (rhBMP-2) derived from a recombinant Chinese Hamster Ovary (CHO) cell line [FDA Label]. … Dibotermin alfa was approved by the EMA in 2002 as Inductos for implantation matrix. In 2004, it was approved by the FDA and is marketed as Infuse.

    Categories: dibotermin alfaSynonyms: Dibotermin alfa, Dibotermina alfa